CLVS

12/17/2021 2.71Highest 2.93

 

Christmas and coronavirus

 It’s looking like chances that the holiday season would be different from last year are fading. Though booster vaccinations are still seen as a bulwark against serious illness from the latest mutation of the coronavirus, fears of an unprecedented wave continue to grow along with the global rate of infection, which now matches the height of the summer delta wave. The U.K., which has been overwhelmed by the new omicron strain, is seen as a harbinger of things to come everywhere else. On Thursday, France said it will ban tourists and almost all business travelers from Britain in a bid to slow the spread. The plan comes after the U.K. recorded its highest number of new cases since the beginning of the crisis. Here’s the latest on the pandemic. —David E. Rovella

Volume

Progenity

 7:29a ET 12/2/2021 - Globe

Newswire

Progenity Announces New Patent for Single-Molecule Detection Technology

Mentioned:

PROG

Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today announced a new patent related to its single-molecule detection platform under development.

The USPTO has issued U.S. Patent No. 11,186,863 entitled, "Methods, Systems, and Compositions for Counting Nucleic Acid Molecules." The issued claims cover methods for capturing, amplifying, and imaging single copies of target nucleic acid molecules.

"This patent covers critical methods for counting target molecules, obviating the need for sequencing," said Matthew Cooper, General Manager, Diagnostics. "Our Single-Molecule Detection Platform is designed to enable tests such as noninvasive prenatal testing (NIPT) or liquid biopsy for cancer to be performed without the need for costly, complex sequencing, which would greatly reduce cost and simplify operational implementation. The platform also has potential applications beyond nucleic acids, such as proteins. As Progenity migrates away from the commercial diagnostics business, we are actively seeking partners to further develop this promising asset."

Progenity has developed a strong patent portfolio supporting its single-molecule detection platform, including six distinct patent families that cover different aspects of the company's molecular counting platform and a separate family directed to detecting nucleosomal positioning patterns, which can be useful for determining cell-free DNA tissue-of-origin. These patents are part of Progenity's corporate portfolio consisting of 96 patent families, including 180 issued patents and more than 220 pending applications. The portfolio includes patents and applications directed to methods and devices for drug delivery, methods and devices for GI sampling and diagnostics, methods and compositions for treating disease, and molecular and protein tools, assays and diagnostics.

About Progenity

Progenity, Inc. is a biotechnology company innovating in the fields of women's health, gastrointestinal health and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity's vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

For more information visit www.progenity.com, or follow the company on LinkedIn or Twitter.

Forward Looking Statements

This press release contains "forward-looking statements," which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts, included in this press release are forward-looking statements. Forward-looking statements include statements regarding Progenity's products under development and the potential uses for such products in the United States and globally. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause Progenity's actual results to differ materially from the forward-looking statements expressed or implied in this press release, including Progenity's ability to successfully develop and commercialize its products under development, the uncertainties inherent in the development process, such as the regulatory approval process, the timing of regulatory filings, the ability to identify potential partners and other matters, including the ongoing COVID-19 pandemic, that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations and the availability or commercial potential of Progenity's products, and those risks described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Progenity's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 18, 2021, and other subsequent documents we file with the SEC, including but not limited to Progenity's Quarterly Reports on Form 10-Q. Progenity claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Progenity expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:

Robert Uhl

Managing Director, Westwicke ICR

ir@progenity.com

(619) 228-5886

Media Contact:

Kate Blom-Lowery

CG Life

media@progenity.com

(619) 743-6294

https://ml.globenewswire.com/media/13988ec5-229f-4a2f-a50d-9562345f284e/small/progenitylogo-jpg.jpg

https://ml.globenewswire.com/media/13988ec5-229f-4a2f-a50d-9562345f284e/small/progenitylogo-jpg.jpg

COMTEX_398162850/2010/2021-12-02T07:29:18

ANY update

 

$4.25

ANY 1

1D 1W 1M 3M 1Y 5Y V

Your position

Shares Market value

108.1 $459.42

Avg cost Portfolio diversity

$6.74 4.29%

Today's return +$36.75 (+8.70%)

Total return - $269.59 (-36.98%)

Today's volume

5,270,835 Trade

PHUN history

 

3 april 2024

 Key statistics
Market cap
65.66M
Price-Earnings ratio
-0.44
Dividend yield
—
Average volume
1.07M
High today
$8.39
Low today
$7.80
Open price
$8.20
Volume
355.63K
52 Week high
$17.99
52 Week low
$0.07

Trading Trends

PHUN up after hour

 

11/11/2021 Dip day

 

FILL THE SHORT

  

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
14	ATOS	10/26/2021	4:00:00 PM	$2.82	$54.12	$152.62	$2.64	($0.18)	($9.74)	$2.64	$500.00	$1,320.00	$1,472.62	$554.12	$2.66	(6.52% NET LOSS GAP 6 CENT )IF 3TIMES FILLED WILL BE GAP 5 CENT

 TO BUY ATHE (ATHE DOWN TODAY normally its running around 1.31 to 1.35 

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
17	AGE	10/26/2021	4:00:00 AM	$1.47	$202.00	$296.94	$0.86	($0.61)	($123.06)	$0.86	$400.00	$344.32	$641.26	$602.00	$1.07	GAP 19CENT (FILL FROM 41%)CURRENT GAP 61CENT
18	AGE	10/26/2021	4:00:00 AM	$1.47	$202.00	$296.94	$0.86	($0.61)	($123.22)	$0.86	$800.00	$688.00	$984.94	$1,002.00	$0.98	GAP 13CENT (FILL FROM 41%)

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
15	ACST			$6.12	$126.00	$771.12	$1.69	($4.43)	($558.18)	$1.69	$1,200.00	$2,028.00	$2,799.12	$1,326.00	$2.11

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
15	ACST			$6.12	$126.00	$771.12	$1.69	($4.43)	($558.18)	$1.69	$5,000.00	$8,450.00	$9,221.12	$5,126.00	$1.80

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
12	BBIG	10/26/2021	2:49:00 AM	$0.60	$53.00	$31.69	$0.44	($0.16)	($8.53)	$0.44	$500.00	$218.50	$250.19	$553.00	$0.45	(IF 3 TIMES 5CENT GAP) IF FOUR TIMES 4 CENT GAP (26PERCENT 10 TIMES 2 CENT GAP

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
8	ATHE	10/26/2021	2:19:00 PM	$1.35	$22.00	$29.70	$1.23	($0.12)	($2.64)	$1.23	$44.00 DOUBLE COVER		$54.12	$83.82	$66.00	$1.27	2CENT GAP

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
9	UTSI	10/26/2021     SELL OFF 1 SHARE PRICE STUDY	2:22:00 PM	$1.21	$1.10	$1.33	$1.30	$0.09	$0.10							SELL OFF TO GET IN AGAIN

BKR

 U.S. Oil-Rig Count Falls by Two in Latest Week, Baker Hughes Says

Mentioned:

BKR

By Dave Sebastian

The number of rigs drilling for oil in the U.S. fell by two in the latest week to 443, according to oil-field services company Baker Hughes Co.The oil-rig count was 232 higher than a year earlier, Baker Hughes said Friday.The nation's gas-rig count rose by one to 99 in the latest week, and was up by 26 compared with the same week last year.The U.S. offshore-rig count rose by one to 13 this week and is unchanged from the year-ago period.The U.S. oil-rig count is viewed as a proxy for activity in the sector. The metric peaked at 1,609 in October 2014.Global oil benchmark Brent crude rose to about $85.46 a barrel Friday. West Texas Intermediate crude, the U.S. benchmark, rose to about $83.64 a barrel.dave.sebastian@wsj.comWrite to Dave Sebastian at dave.sebastian@wsj.com

INFO

 Service-Sector Strength Aids Global Growth

Mentioned:

INFO

By Paul Hannon and David Harrison

Business activity accelerated in some of the world's largest economies owing to a pickup in the services sector that has offset weakness in manufacturing caused by supply-chain bottlenecks and rising prices.Surveys of purchasing managers conducted over recent weeks point to increased growth in the U.S., Japan and Australia due to easing fears of the Delta variant of Covid-19.In Europe, however, growth slowed due to reduced factory activity as businesses reported difficulties getting hold of the parts and raw materials they needed.That combination likely means the global economy will continue to recover in the final months of the year, but not at the pace reached in the second quarter, when reopenings led to a growth spurt.Private data firm IHS Markit said Friday that its composite Purchasing Managers Index for the U.S. rose to a three-month high of 57.3 in October from 55 in September. A reading above 50 indicates growth, while a level below 50 signals contraction.In the eurozone, the PMI fell to a six-month low of 54.3 in October from 56.2 in September. U.S. growth was driven by the service sector, which hired at the quickest pace since June, the IHS survey showed. Businesses said they were struggling to meet increased demand because of supply-chain backups and a shortage of available workers. Manufacturing activity in the U.S. slowed in October with firms reporting longer delivery times. Figures for gross domestic product to be released in the U.S. and Europe next week are expected to point to a slowdown in the three months through September. Economists surveyed by The Wall Street Journal expect the U.S. economy grew at a seasonally adjusted annual rate of 3.1% in the third quarter, down from 6.7% in the second quarter.China reported a sharp slowdownEarlier this week, China reported a sharp slowdown in growth in the third quarter, when the economy expanded 4.9%, compared with 7.9% during the previous three months, in part due to supply-chain problems and energy shortages.Input prices rose steeply because of supply problems, higher labor and shipping costs and a shortage of raw materials. The U.S. consumer-price index rose 5.4% in September from the previous year, the Labor Department reported earlier this month.'While the economy looks set for stronger growth in the fourth quarter, the upward rise in inflation pressures also shows no sign of abating,' said Chris Williamson, chief business economist at IHS Markit. hit a 13-year highFor European factories, delivery times for inputs lengthened and their prices increased at a record pace. The eurozone's annual rate of inflation hit a 13-year high in September and is set to move even higher before the end of the year. However, many economists continue to view the acceleration in price rises as a temporary problem that will be resolved when factories world-wide have had the time to add capacity and meet strong consumer demand.The International Monetary Fund on Wednesday said Europe's major central banks shouldn't rush to raise their key interest rates to tackle the inflation surge.'Our view is that monetary policies in most economies should remain highly accommodative because employment has yet to reach precrisis levels and there are few signs that price increases are translating into broad-based wage pressures,' said Alfred Kammer, head of the International Monetary Fund's European department.Japanese and Australian businesses also report supply shortages and rising costs, but in both countries the surveys of purchasing managers pointed to a pickup in growth as restrictions imposed earlier in the year were eased. The composite PMI for Japan increased to 50.7 in October from 47.9 in September, indicating a return to growth.'With virus cases having receded substantially from the record high levels seen in August, and state of emergency conditions in many prefectures removed at the end of last month, today's Japanese flash PMIs for October cast the economy in a much stronger light than in recent months,' economists at Daiwa Capital Markets wrote in a note to clients.The Australian measure rose to 52.2 in October from 46.0 in September, also pointing to a return to growth after the lifting of restrictions.paul.hannon@wsj.comWrite to Paul Hannon at david.harrison@wsj.compaul.hannon@wsj.com and David Harrison at david.harrison@wsj.com

CME

 CME Group Inc. Cl A Stock Rises Friday, Outperforms Market

Mentioned:

CME

This article was automatically generated by MarketWatch using technology from Automated Insights. 

Shares of CME Group Inc. Cl A (CME) advanced 1.47% to $217.95 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.21% to 35,677.02 and the S&P 500 Index falling 0.11% to 4,544.90. This was the stock's second consecutive day of gains. CME Group Inc. Cl A closed $3.87 below its 52-week high ($221.82), which the company achieved on June 1st. 

The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Intercontinental Exchange Inc. (ICE) rose 1.54% to $131.60, MSCI Inc. (MSCI) rose 1.99% to $649.09, and Nasdaq Inc. (NDAQ) rose 1.44% to $201.72. Trading volume (1.2 M) remained 162,429 below its 50-day average volume of 1.3 M. 

Data source: Dow Jones Market Data, FactSet. Data compiled October 22, 2021. 

-MarketWatch Automation 

(END) Dow Jones Newswires

October 22, 2021 16:44 ET (20:44 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.

To buy

 

SPCE

 

PLRD

 12:55p ET 10/7/2021 - Benzinga

Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

Mentioned:

PRLD

• Prelude Therapeutics Inc (NASDAQ: PRLD) has announced data from the dose-escalation portions of Phase 1 trials of PRT543 and PRT811. 
• The data will be featured at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
• PRT543 demonstrated target engagement and inhibition of PRMT5 functional activity, evidenced by a 69% reduction in serum symmetric dimethylarginine (sDMA) at a dose of 45 mg/5x per week. 
• One complete response (CR) was maintained for over 18 months in a patient with HRD+ ovarian cancer.
• Stable disease (SD) persisting for over six months was seen in five patients, including four with adenoid cystic carcinoma (ACC) and one with uveal melanoma. 
• The most common grade 3 or higher treatment-related adverse events were thrombocytopenia (27%) and anemia (12%), reversible upon treatment interruption. 
• PRT811 demonstrated dose-dependent inhibition of PRMT5 activity, evidenced by an 83% reduction in serum sDMA at 600 mg daily. 
• PRT811 demonstrated signs of preliminary clinical activity, including an IDH1 mutated GBM patient who experienced a partial response (PR) that evolved into a durable CR for more than 13 months.
• One patient with splicing-mutant (SF3B1) uveal melanoma demonstrated SD for more than six months with a 25% tumor regression and remains on treatment. 
• One additional patient (800 mg twice daily) with SF3B1 uveal melanoma had an unconfirmed PR and 47% decrease in target lesion. 
• A patient with triple-negative breast cancer (800 mg QD) demonstrated a 27% decrease in target lesions. 
• Related: Why BofA Is Turning Bullish On Prelude Therapeutics.
• Price Action: PRLD stock is down 33.3% at $19.20 during the market session on the last check Thursday.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

GTE

 

ACST

CRASH STUDY

ID	STOCK	DATE	TIME	your avg	market price	AMOUNT	TOTAL EQUITY	Field4	MARKET PRICE	CURRENT PRICE	AMT(NT)	NL	FILL PRICES	FILLED AMOUNT	FILLED TOTAL	Field2	TOTAL SHARE	Field3	AVG	REMARK NET LOSS
386	acst	9/10/2021	1:59:34 PM	$3.68	$2.35	101.00	$371.31	Net loss 36.07	$2.35	($1.33)		($133.96)
387	ACST	9/1/1021	1:59:34 AM	$6.12	$2.35	126.00	$771.12	NET LOSS 61.57 TO FILL	$2.35	($3.77)		($475.02)

CRASH STUDY TDameritrade 

ID	STOCK	DATE	TIME	your avg	market price	AMOUNT	TOTAL EQUITY	Field4	MARKET PRICE	CURRENT PRICE	AMT(NT)	NL	FILL PRICES	FILLED AMOUNT	FILLED TOTAL	Field2	TOTAL SHARE	Field3	AVG	REMARK NET LOSS
386	acst	9/10/2021	1:59:34 PM	$3.68	$2.35	101.00	$371.31		$2.35	($1.33)		($133.96)